Related Experiment Video
Updated: May 19, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Testosterone replacement and prostate cancer
Ranjith Ramasamy1, Erik S Fisher, Peter N Schlegel
1Department of Urology, New York - Presbyterian Hospital, Weill Cornell Medical College, New York, USA.
Summary
Testosterone replacement therapy does not appear to be an independent risk factor for prostate cancer. This therapy may offer cardiovascular benefits and improve body composition and insulin resistance in men with hypogonadism.
Area of Science:
- Endocrinology
- Urology
- Oncology
Background:
- Controversy exists regarding the association between exogenous androgen administration and prostate cancer risk.
- Androgen replacement therapy (ART) is used to treat symptomatic hypogonadism.
Purpose of the Study:
- To review available clinical data on the risks and benefits of testosterone (androgen) replacement therapy.
- To specifically address the relationship between exogenous androgen administration and prostate cancer risk.
Main Methods:
- Systematic review of existing clinical studies and literature.
- Analysis of data concerning androgen administration and prostate cancer incidence.
- Evaluation of cardiovascular events, body fat mass, and insulin resistance in patients undergoing ART.
Main Results:
- No study definitively demonstrates that androgen replacement therapy is an independent risk factor for prostate cancer development.
- Androgen administration may reduce fatal cardiovascular events.
- ART appears beneficial in decreasing body fat mass and improving insulin resistance.
Conclusions:
- Current clinical data suggest that androgen replacement therapy is a suitable treatment for men with symptomatic hypogonadism.
- Regular prostate screenings are recommended for patients undergoing androgen replacement therapy.
- ART may offer significant health benefits beyond testosterone level restoration.
Related Concept Videos
01:20Disorders of the Male Reproductive System
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:26Testosterone: Functions and Regulation
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...